Aytu bioscience announces completion of healight(tm) safety study in critically ill covid-19 patients

First safety study utilizing ultraviolet a light catheter as a prospective anti-infective in critically ill, intubated sars-cov-2 patients englewood, co / accesswire / december 28, 2020 / aytu bioscience, inc. (nasdaq:aytu), a specialty pharmaceutical company (the "company") focused on commercializing novel products that address significant patient needs announced the completion of the safety study evaluating the healight™ ultraviolet a light catheter technology. this single center, u.s.-based study evaluated the safety and proof of principle of the healight device in newly intubated critically ill patients on mechanical ventilation diagnosed with covid-19.
AYTU Ratings Summary
AYTU Quant Ranking